|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2005-10-5
|
|
pubmed:abstractText |
Beta-2 adrenoceptor antagonists such as timolol have been used in the treatment of glaucoma for more than 30 years. Several functionally important polymorphisms for the beta-2 receptor have been described. In the present study we hypothesized that a relation between the intraocular pressure (IOP) lowering effect of timolol and beta-2 adrenoceptor polymorphisms may exist.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1090-0535
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
811-5
|
|
pubmed:meshHeading |
pubmed-meshheading:16205624-Administration, Topical,
pubmed-meshheading:16205624-Adrenergic beta-Antagonists,
pubmed-meshheading:16205624-Adult,
pubmed-meshheading:16205624-Blood Pressure,
pubmed-meshheading:16205624-DNA Mutational Analysis,
pubmed-meshheading:16205624-Genotype,
pubmed-meshheading:16205624-Heart Rate,
pubmed-meshheading:16205624-Humans,
pubmed-meshheading:16205624-Intraocular Pressure,
pubmed-meshheading:16205624-Male,
pubmed-meshheading:16205624-Ophthalmic Solutions,
pubmed-meshheading:16205624-Polymorphism, Genetic,
pubmed-meshheading:16205624-Receptors, Adrenergic, beta-2,
pubmed-meshheading:16205624-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:16205624-Timolol,
pubmed-meshheading:16205624-Tonometry, Ocular
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Polymorphism of the beta-2 adrenoceptor and IOP lowering potency of topical timolol in healthy subjects.
|
|
pubmed:affiliation |
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
|
|
pubmed:publicationType |
Journal Article
|
